CompuMed, Inc.
CMPD · OTC
3/31/2025 | 12/31/2024 | 9/30/2024 | 6/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.14 | -2.29 | -0.57 | 0.14 |
| FCF Yield | -8.34% | -1.21% | 1.57% | 10.50% |
| EV / EBITDA | 14.94 | 19.35 | 17.08 | 6.12 |
| Quality | ||||
| ROIC | 1.46% | 0.74% | 0.83% | 2.83% |
| Gross Margin | 45.40% | 46.83% | 47.31% | 48.65% |
| Cash Conversion Ratio | 5.47 | 2.49 | 8.26 | 5.04 |
| Growth | ||||
| Revenue 3-Year CAGR | 3.22% | 0.77% | -0.76% | -1.01% |
| Free Cash Flow Growth | -585.87% | -181.16% | -73.60% | 76.40% |
| Safety | ||||
| Net Debt / EBITDA | -1.92 | -4.75 | -4.76 | -3.39 |
| Interest Coverage | 5.63 | 2.40 | 2.60 | 14.35 |
| Efficiency | ||||
| Inventory Turnover | 5.80 | 3.13 | 3.78 | 2.14 |
| Cash Conversion Cycle | 33.49 | 47.35 | 50.74 | 45.26 |